drugset / Trial / NCT06451640
A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps
Phase 2
Completed
59 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study aims to evaluate the efficacy and safety of TQC2731 injection in the treatment of chronic sinusitis with nasal polyps.
Timeline
- Start
- 2024-07-04
- Primary completion
- 2025-10-17
- Completion
- 2025-10-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQC2731 | Monoclonal antibody | 210 mg | — |
| Subject | TQC2731 | Monoclonal antibody | 420 mg | — |